Characterizing an alternatively spliced NTRK2 isoform in development and cancer
Characterizing an alternatively spliced NTRK2 isoform in development and cancer
批准号:
10191906
负责人:
Siobhan Pattwell
金额:
$18.71万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-09-24 至 2024-08-31
关键词:
AddressAgeAlternative SplicingAnatomyAntibodiesAutomobile DrivingBindingBiologyCancer EtiologyCellsDataDevelopmentDevelopmental ProcessDiagnosticEmbryoEmbryonic DevelopmentErinaceidaeEventFoundationsFutureGliomaGoalsHumanIn VitroLeadLentivirus VectorLifeLightLinkMaintenanceMalignant NeoplasmsMolecularMusMutagenesisNTRK2 geneNeoplasm MetastasisNerve Growth Factor ReceptorsNervous system structureNeurophysiology - biologic functionOncogenesOncogenicOrganOrganogenesisPTEN genePathway interactionsPatternPhosphotransferasesPlatelet-Derived Growth FactorProcessProtein IsoformsProteinsRNA SplicingReagentRoleSeriesSignal PathwaySignal TransductionTherapeuticTimeTissuesTranscriptTumor BiologyVariantWorkcancer initiationcancer typecareercombinatorialcourse developmentexperimental studyin vitro activityin vivoindexingloss of functionmembermouse modelneglectnerve stem cellneurodevelopmentneurotrophic factornotch proteinnovelnovel diagnosticsoverexpressionpostnatalpostnatal developmentreceptorsynaptic pruningtherapeutic targettranscriptome sequencingtumortumorigenesisvector
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract
The link between developmental signaling and cancer initiation, maintenance and metastasis has long been
known for several members of the Wnt, Hedgehog, and Notch pathways. The possibility remains that a
developmentally-regulated splicing event may share similar features with these oncogenic pathways, driving
normal development in an anatomically appropriate, temporally restricted context, and causing cancer when
dysregulated. We have recently shown that a kinase-deficient NTRK2 neurotrophin receptor splice variant,
TrkB.T1, predominates in glioma and amplifies several oncogenic signaling pathways. Our preliminary data
suggest that TrkB.T1 is the predominate NTRK2 isoform expressed across multiple organs during embryonic
development, is highly expressed in various cancer types in humans, and when over-expressed in combination
with PTEN loss, causes a wide range of cancers in mice. The project proposed here seeks to characterize the
role TrkB.T1 in development and cancer using a novel antibody and a novel mouse model to show that specific
splice variants are oncogenic when overexpressed, postnatally, in the specific organs that expressed them
during development. By perturbing cell-specific TrkB.T1 splice variant expression in mice, embryonically, and
using single cell combinatorial indexing RNA-sequencing analysis to follow NTRK2 transcripts across embryonic
and postnatal development, I aim to (1) link developmental mechanisms and splicing choices to cancer, (2) link
a kinase deficient protein with increases in signaling, and (3) seek to discern whether trapping cells in a particular
developmental state can lead to cancer. By further characterizing the mechanism by which TrkB.T1 functions,
these projects have the potential to open new avenues for diagnostic and therapeutic targets for multiple cancer
types. The experiments proposed here build upon my previous work in neurodevelopment, neurotrophin biology,
and cancer and will help set the stage for my long-term career goals which center around employing a
developmentally guided approach to studying neurotrophic contributions to tumor biology and uncovering
developmental influences on oncogenesis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Characterizing an alternatively spliced NTRK2 isoform in development and cancer
-
批准号:10855131
-
项目类别:
-
资助金额:$7.56万
-
财政年份:2023
-
负责人:Siobhan Pattwell
-
依托单位:
Characterizing an alternatively spliced NTRK2 isoform in development and cancer
-
批准号:10688049
-
项目类别:
-
资助金额:$18.71万
-
财政年份:2021
-
负责人:Siobhan Pattwell
-
依托单位:
Characterizing an alternatively spliced NTRK2 isoform in development and cancer
-
批准号:10490261
-
项目类别:
-
资助金额:$18.71万
-
财政年份:2021
-
负责人:Siobhan Pattwell
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: